Thomas Trimarchi - 10 Dec 2024 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role: President and COO
Signature: /s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol: BBIO
Transactions as of: 10 Dec 2024
Transactions value $: $0
Form type: 4
Filing time: 12 Dec 2024, 19:00:03
Previous filing: 19 Nov 2024
Next filing: 19 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BBIO	Common Stock	Award	$0	+50K	+13.23%	$0.00	428K	10 Dec 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSU's have no expiration date.
F2	Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Content

Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest with respect to 1/2 of the underlying shares on December 12, 2025. Thereafter, the remaining underlying shares shall vest on December 12, 2026, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSU's have no expiration date.

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.